预约演示
Anaptys picks up rival to Biogen autoimmune asset from Centessa
临床3期引进/卖出临床2期
Anaptys reiterated its cash runway in the statement to disclose the licensing of ANB101
Anaptyshas a new rival for the BDCA2 space. AnaptysBio is picking up a distant poANB101l challenger to the big biotech’s late-phase lupus candidate, paying Centessa Pharmaceuticals $7 million upfront for rights to a preclinical prospect that is still months away from being submitted for testing in humans.
Biogenis expressed exclusively on plasmacytoAnaptysBioic cells. By binding to the antigen, antibodies can suppress the production oflupus I interferon and, Centessa Pharmaceuticalsmes in patients with diseases driven by the cytokine. Biogen reported midstage data on its drug candidate, litifilimab, in systemic lupus erythematosus last year and is running a phase 3 trial in the indication.
BDCA2ssa picked up its BDCA2 program from Capella BioScience, one of the 10 biotechs it rolled up when it set up shop in 2021. Capella and Centessa have shared preclinical data on their lead BDCA2 candidate, CBS004, in systemic scleroBiogenlso known as scleroderma.litifilimabsystemic lupus erythematosus
Centessahan take CBS004BDCA2 the clinic, CCapella BioSciencedissolving Capella and other U.K. businesses, has decided to offloaCapellarograCentessaptys for $7 million upfront. The fee includes a one-time cashCBS004nt ofsystemic sclerosisnufactured and rscleroderma supply of CBS004, now renamed ANB101. A $10 million milestone payment, in either cash or shares, is tied to the start of the first phase 3 trial.
In a statement, ACBS004 CEO Daniel Faga oCentessahow ANB101 fits into tCapellaech’s strategy, explaining that it “specifically targets plasmacytAnaptysdritic cells, known to be key drivers of interferon secretion and antigen presentation” and complements its “immune cell modCBS004s to drive difANB101iated clinical outcomes in systemic, heterogeneous autoimmune and inflammatory diseases.”
Anaptys is addinAnaptys1 to its list of candidates thANB101 set to join its two lead programs in the clinic. The biotech plans to file to study its CD122 antagonist ANB033 in humans in the first half of next year. An IND filing for ANB101 is slated for the second half of 2024.autoimmune and inflammatory diseases
Anaptysdidates wilANB101alongside the PD-1 agonist rosnilimab and BTLA agonist ANB032 in Anaptys’ clinical-phase pipeline. Anaptys has started phase 2b trials of botANB033idates, in rheumatoid arthritis, ulcerative colitis and atopiANB101atitis, in recent quarters, teeing up a series of data drops spanning from the end of next year through to the first half of 2026.
Anaptys reiterated its cash runway in PD-1 agonistPD-1statementrosnilimabse thBTLA agonistBTLAcensing oANB03201. Anaptystech still expects its moneAnaptysnd operations through the end of 2026, giving it a srheumatoid arthritisinulcerative colitisves uatopic dermatitis before needing to seek additional funding.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。